Company Description
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.
Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.
The company is headquartered in Cardiff, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Mark Andrew Rothera |
Contact Details
Address: 2533 S Coast Hwy 101, Suite 210 Cardiff, California 92007 United States | |
| Phone | 858-400-8470 |
| Website | viracta.com |
Stock Details
| Ticker Symbol | VIRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001061027 |
| CUSIP Number | 92765F108 |
| ISIN Number | US92765F1084 |
| Employer ID | 94-3295878 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark Andrew Rothera | Chief Executive Officer, President and Director |
| Dr. Susan Perrine M.D. | Scientific Founder and Consultant |
| Dr. Ronald J. Berenson M.D. | Co-Founder and Consultant |
| George Hillman | Co-Founder |
| Dr. Thalia Papayannopoulou M.D. | Co-Founder |
| Dr. Robert M. Williams Ph.D. | Co-Founder |
| Dr. Douglas V. Faller M.D., Ph.D. | Scientific Founder and Chairman of Scientific Advisory Board |
| Melody Burcar CPA, M.B.A. | Senior Vice President of Finance, Interim Principal Financial Officer and Interim Principal Accounting Officer |
| Dr. Ayman El-Guindy | Chief Scientific Officer |
| Stewart M. Brown | Senior Vice President of Legal Affairs and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 8-K | Current Report |